Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA coul | Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve ...

This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...